Targeted sequencing data of ARID1A in UC patients

We analyzed data from over 600 patients and demonstrated that the combination of ARID1A loss and high CD8⁺ T cell infiltration defines a distinct subgroup of urothelial carcinoma (UC) with markedly improved survival and enhanced sensitivity to both chemotherapy and PD-1/PD-L1 blockade.

我们对超过600例患者的临床数据进行分析，证实ARID1A缺失联合CD8阳性T细胞高浸润，可定义尿路上皮癌（urothelial carcinoma，简称UC）的独特亚群，该亚群患者生存期显著延长，且对化疗与PD-1/PD-L1阻断治疗均表现出更高的敏感性。